Sellas Life Sciences Group Inc (SLS)
Sellas Life Sciences Group Inc. (NASDAQ: SLS) is a late-stage clinical biopharmaceutical company focused on developing novel cancer therapies in the United States. Its pipeline includes galinpepimut-S (GPS), a peptide immunotherapy targeting the Wilms tumor 1 antigen, and SLS009 (tambiciclib), a selective small-molecule CDK9 inhibitor. The company is also advancing GPS in combination with Merck & Co.’s PD1 blocker pembrolizumab in a Phase 1/2 trial that is enrolling patients across up to five cancer indications, including hematologic malignancies and solid tumors. In addition, SELLAS has a strategic collaboration with GenFleet Therapeutics (Shanghai), Inc. related to the development and commercialization of GFH009. The company is headquartered in New York, New York.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-SLS
|
$6.99
|
-43.7% Downside
|
Overvalued
|
$27.50
|
121.4% Upside
|
Bargain
|
Good
|
—
|
—
|
—
|
0.0%
|
August 6, 2026
|
-83.0x
|
22.8x
|
—
|
2.453 B
|
2.34 B
|
0.0%
|
99.6%
|
214.3
|
—
|
95.6%
|
